All In Biotech

Drug Trial Radar · NCT00328380

Prevention of Travelers' Diarrhea in Subjects Traveling Outside the U.S.

A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety of Rifaximin for the Prevention of Travelers' Diarrhea in Subjects Traveling Outside the United States

Last checked: Nov 20, 2026Latest source record: Nov 25, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 660 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

660

Planned (sponsor's estimate)

Start

Dec 2005

Primary completion

Dec 2006

Study completion Sep 2008

Sponsor

Lead sponsor
Bausch Health Americas, Inc.Industry
Sponsor type
Industry
First posted
May 19, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Prevention
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of this study is to assess the safety and tolerability of rifaximin 600 mg (3 x 200-mg tablets) once daily compared with placebo when taken for 14 days by healthy subjects to prevent travelers' diarrhea (TD) from all causes.

Conditions

  • Diarrhea

Interventions

  • RifaximinDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary endpoint in this study is the assessment of safety and tolerability of rifaximin 600 mg QD compared to placebo.

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Sunshine Medical Center

    South Miami, Florida

  • Southwest Doctors, PA

    Houston, Texas

  • La Porte Family Clinic

    La Porte, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.